Payment overview · 2025
General Payments
$312.00
16 reported records · 5 companies
Healthcare provider profile · identity verified
Simran K. Arora, MD
Allopathic & Osteopathic Physicians|General Practice · GARY, IN · NPI 1578976791
Verified facts
What the public records show
CMS Open Payments records show Simran K. Arora, MD received $312.00 in general payments during 2025 across 16 reported records.
Gilead Sciences, Inc. accounted for 57.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $178.75 | 57.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.53 | 13.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.80 | 11.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.10 | 10.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.82 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.00 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1054 | 336 |
| Amlodipine Besylate | Amlodipine Besylate | 621 | 193 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 413 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 399 | 125 |
| Montelukast Sodium | Montelukast Sodium | 369 | 132 |
| Gabapentin | Gabapentin | 295 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 101 |
| Losartan Potassium | Losartan Potassium | 284 | 93 |
| Metformin Hcl | Metformin Hcl | 262 | 85 |
| Furosemide | Furosemide | 260 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 70 |
| Carvedilol | Carvedilol | 230 | 69 |
| Lisinopril | Lisinopril | 224 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 223 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 52 |
| Potassium Chloride | Potassium Chloride | 214 | 65 |
| Tramadol Hcl | Tramadol Hcl | 211 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 62 |
| Ozempic | Semaglutide | 194 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 67 |
| Glipizide | Glipizide | 187 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 172 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 165 | 58 |
| Meloxicam | Meloxicam | 162 | 44 |
| Omeprazole | Omeprazole | 144 | 47 |
| Alendronate Sodium | Alendronate Sodium | 136 | 43 |
| Prednisone | Prednisone | 136 | 96 |
| Azithromycin | Azithromycin | 128 | 92 |
| Allopurinol | Allopurinol | 124 | 37 |
| Pregabalin | Pregabalin | 120 | 32 |
| Alprazolam | Alprazolam | 117 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 22 |
| Famotidine | Famotidine | 104 | 43 |
| Trazodone Hcl | Trazodone Hcl | 104 | 28 |
| Farxiga | Dapagliflozin Propanediol | 102 | 28 |
| Sertraline Hcl | Sertraline Hcl | 96 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 24 |
| Ibuprofen | Ibuprofen | 74 | 31 |
| Memantine Hcl | Memantine Hcl | 73 | 25 |
| Meclizine Hcl | Meclizine Hcl | 68 | 28 |
| Methylprednisolone | Methylprednisolone | 67 | 63 |
| Ezetimibe | Ezetimibe | 64 | 20 |
| Naproxen | Naproxen | 64 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 16 |
| Entresto | Sacubitril/Valsartan | 56 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 24 |
| Nifedipine Er | Nifedipine | 53 | 12 |
| Cilostazol | Cilostazol | 52 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 28 |
| Chlorthalidone | Chlorthalidone | 50 | 15 |
| Buspirone Hcl | Buspirone Hcl | 48 | 12 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 17 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Fluconazole | Fluconazole | 44 | 23 |
| Mounjaro | Tirzepatide | 44 | 17 |
| Eliquis | Apixaban | 43 | 15 |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Linzess | Linaclotide | 41 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Glimepiride | Glimepiride | 37 | 12 |
| Levetiracetam | Levetiracetam | 37 | 12 |
| Glipizide Er | Glipizide | 36 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 16 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 12 |
| Cephalexin | Cephalexin | 29 | 26 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 14 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nyamyc | Nystatin | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Spironolactone | Spironolactone | 25 | 11 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.00 · 16 records | Gilead Sciences, Inc. | Cologuard Collection Kit, MOUNJARO, REPATHA, REXULTI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error